sunday, february 23 *-Short talk from proffered abstract registration 12-9 p.m. EDUCATIONAL SESSIONS 1 AND 2 3:30-4:50 p.m. educational session 1: detection of tumor-reactive t cells Session Chair: Stephen Schoenberger, La Jolla Institute for Immunology, La Jolla, California EDUCATIONAL SESSION 2: Strategies to Overcome Manufacturing Challenges for Cell-Based Therapy Session Chair: Marc Better, Pharmefex, Bellevue, […]
Zongertinib demonstrated durable efficacy in patients with pretreated advanced HER2-mutant non–small cell lung cancer.
The phase 3 randomized controlled trial of extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (PM) (MARS2) reported “extended pleurectomy decortication was…
In this issue of Blood, Ito et al1 present a compelling cost-effectiveness analysis of iptacopan for patients with paroxysmal nocturnal hemoglobinuria (PNH
Curtis Lachowiez, MD, Oregon Health & Science University, Portland, OR, comments on a retrospective analysis assessing the efficacy of combining venetoclax with intensive purine analog-based…
Olverembatinib demonstrated preliminary efficacy and was well tolerated in patients with heavily pretreated chronic-phase myeloid leukemia.
Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.
The phase 3 MECCA trial represents the largest data set investigating the efficacy of metronomic chemo-endocrine combination therapy in metastatic breast cancer, according to researchers.
The FDA has issued a draft guidance offering recommendations regarding tissue biopsies in clinical trials for pediatric and adult patients.
When it comes to cancer prevention and early detection, knowledge can be power.
